Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Alessa Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06257693
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
Phase 1
Active, not recruiting
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Radiation: Stereotactic body radiation therapy
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Alessa Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04943536
- Locations
- ๐บ๐ธ
National Cancer Institute, Bethesda, Maryland, United States
A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer
Phase 1
Completed
- Conditions
- Prostate AdenocarcinomaLower Urinary Tract Symptoms
- Interventions
- Combination Product: Bicalutamide implant
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Alessa Therapeutics Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04284761
- Locations
- ๐ฆ๐บ
Australian Clinical Trials, Wahroonga, New South Wales, Australia
๐ณ๐ฟTauranga Urology Research, Tauranga, North Island, New Zealand
๐บ๐ธNational Institutes of Health Clinical Center, Bethesda, Maryland, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath